|Videos|March 3, 2020

Potential Complications from Flu

Jason Gallagher, PharmD, discusses the risk factors for experiencing complications of influenza.

Segment Description: Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, clinical professor at Temple University College of Pharmacy and editor-in-chief of Contagion®, discusses the risk factors for experiencing complications of influenza.

Transcript (modified slightly for readability):

Gallagher: Most years the mortality rate from influenza is a U shaped curve where the mortality is the highest in the very young and in elderly patients and that's due to immune response, but also comorbid diseases, particularly in the elderly. Comorbidities are really what people put people at the highest risk of complications from influenza. Asthma, COPD, other pulmonary conditions, even heart conditions, and the immunocompromised population, all of these patients are at a significantly higher risk of complications from influenza than the general population.

It's such a list that if you were to break it down before it was recommended to be given universally, if you just look at this special populations that the influenza vaccine was recommended for, it's so many people that it just makes more sense to vaccinate everyone anyway. While everybody should get a flu shot, people with those types of comorbidities are at the highest risk of complications, and it's essential that we vaccinate them.


Related to this article

REMAP-CAP and the Tamiflu “Pre-Release”: A Set-Up for Disaster
Preliminary REMAP-CAP data suggesting oseltamivir may increase mortality in critically ill ICU influenza patients has sparked polarized reactions, but clinicians should await the full peer-reviewed manuscript before drawing broad conclusions, since the signal comes from a narrow, severely ill population and may reflect a therapeutic window effect rather than a blanket lack of efficacy.
GSK's mRNA Influenza Vaccine Moves to Phase 3 Trial
GSK will advance its investigational mRNA seasonal flu vaccine candidate, which targets both hemagglutinin and neuraminidase, into a phase 3 trial in September 2026 after the shot outperformed licensed flu vaccines in a phase 2 study.
How The Food Safety Surveillance Infrastructure Works in the US
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.